# Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

Study · id `cardio:ct-nct03702582` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03702582](<https://clinicaltrials.gov/study/NCT03702582>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03702582

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03702582. Randomized; no masking; primary purpose prevention. Start 2019-04-30 (actual); primary completion 2023-10-01 (actual). Results posted on 2026-05-19.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03702582, source copy `cardio:ctgov-nct03702582-2026-05-19`, retrieved 2026-10-26)
- Started: 2019-04-30 (actual) (ClinicalTrials.gov record NCT03702582, source copy `cardio:ctgov-nct03702582-2026-05-19`, retrieved 2026-10-26)
- Primary completion: 2023-10-01 (actual) (ClinicalTrials.gov record NCT03702582, source copy `cardio:ctgov-nct03702582-2026-05-19`, retrieved 2026-10-26)
- Completion: 2023-10-01 (actual) (ClinicalTrials.gov record NCT03702582, source copy `cardio:ctgov-nct03702582-2026-05-19`, retrieved 2026-10-26)
- Results first posted: 2026-05-19 (ClinicalTrials.gov record NCT03702582, source copy `cardio:ctgov-nct03702582-2026-05-19`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03702582, source copy `cardio:ctgov-nct03702582-2026-05-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03702582-2026-05-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
- Acronym: NEW-AF
- Condition: Atrial Fibrillation
- Condition: Stroke
- Condition: Bleeding
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Warfarin
- Lead sponsor: Massachusetts General Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)
- Registry lists this organization as the lead sponsor: Massachusetts General Hospital (`cardio:org-massachusetts-general-hospital`)

## Provenance

Content hash: fd94183819efb824c15ce1f446e12e904137e6ea8ec7c2b05b7fb6342ed5a2b5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
